Jefferies Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Jefferies Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3	Closed	-$73	–	2653
2016 Q3	$0	Sell	3 -91,853	-100%	-$2.86M	﹤0.01%	2599
2016 Q2	$3.53M	Buy	+91,856	New	+$3.81M	0.02%	642
2015 Q4	–	Sell	-3,200	Closed	-$130K	–	2722
2015 Q3	$130K	Buy	3,200 +856	+37%	+$37.5K	﹤0.01%	2015
2015 Q2	$125K	Buy	+2,344	New	+$124K	﹤0.01%	2122

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jefferies Group's JUNO Position: Q4 2016 in Review

Jefferies Group sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 3 shares — an estimated $73 sold.

Jefferies Group first reported a position in JUNO in Q2 2015 and held it in 4 quarters. The position peaked at $3.53M in Q2 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

Jefferies Group reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Jefferies Group sold 3 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $73.
Jefferies Group first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 4 quarters.
Jefferies Group's Juno Therapeutics, Inc. position peaked at $3.53M in Q2 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Jefferies Group's 13F filing for Q4 2016, filed 14 Feb 2017.